GT health — Wise Endocrine & Metabolic Care

Patient MessagingPatients

Dr. Tashko’s infographic highlighting androgen excess in women, featuring a central glowing panel with the title surrounded by a molecular network, flowchart pathways, and icons representing female physiology, genetics, and metabolic processes. The visual conveys a structured clinical framework, integrating hormonal pathways, diagnostic logic, and system-wide interactions within a modern, data-driven endocrine perspective.

These recommendations reflect clinical guidance developed primarily from United Kingdom data and real-world practice patterns. They offer a structured, multidisciplinary approach to evaluating androgen excess in women, while reinforcing the importance of clinical judgment in areas where evidence remains limited.

At a broader level, these guidelines move beyond a checklist mentality. They encourage a more deliberate form of reasoning, one that weighs pattern, pace, and physiology together. In that sense, they align with a more thoughtful and integrated model of endocrine care.

A Structured and Risk-Aware Diagnostic Approach

The guidelines emphasize that androgen excess is common, affecting up to 10% of women of reproductive age. Most cases relate to polycystic ovary syndrome, yet a smaller subset reflects more serious underlying conditions that require timely recognition.

Clinicians should begin with a careful clinical assessment that integrates history, symptom pattern, and tempo of progression. Slowly evolving symptoms beginning in adolescence often suggest PCOS, whereas rapid onset, especially with virilization, raises concern for tumors or severe endocrine disorders.

This distinction carries real clinical weight. It separates a condition that evolves over years from one that may declare itself over months. That difference in timing often becomes one of the most reliable signals in endocrine medicine.

Interconnected Physiology: Ovaries, Adrenals, and Metabolism

The guidelines highlight that androgen biology reflects a dynamic interplay between:

  • Ovarian androgen production
  • Adrenal precursor secretion
  • Peripheral tissue conversion
  • Insulin signaling and metabolic state
  • The 11-oxygenated androgen pathway (an emerging, predominantly adrenal androgen subclass that does not decline post-menopause)

This networked physiology deserves emphasis. Hormones rarely act in isolation, and androgens represent a convergence point where multiple systems intersect. This convergence explains why seemingly isolated symptoms often reflect a broader physiologic imbalance.

Insulin, in particular, plays a central role. It stimulates ovarian androgen production and reduces sex hormone binding globulin, thereby increasing free testosterone levels.

This relationship helps explain why androgen excess often travels alongside insulin resistance, weight changes, and lipid abnormalities. It also reinforces a key clinical insight: treating androgen excess effectively often requires addressing the metabolic terrain beneath it.

Causes: Common First, Rare but Important to Exclude

ConditionDiagnostic CategoryTypical OnsetKey Clinical Clues
Polycystic Ovary Syndrome (PCOS)Common (Up to 10% of women)Insidious (usually since puberty)Mild to moderate hyperandrogenism, irregular cycles; slowly evolving.
Non-Classic Congenital Adrenal HyperplasiaCommon MimicInsidious (puberty or early adulthood)Clinically mimics PCOS; requires 17-OHP screening to differentiate.
Ovarian HyperthecosisLess CommonPostmenopausalSevere insulin resistance, gradually worsening hirsutism or alopecia.
Androgen-Secreting Tumors (Ovarian/Adrenal)Rare but CriticalRapid (declares over months)Sudden onset, overt virilization, extreme testosterone elevation (> 5 nmol/L).
Severe Insulin Resistance SyndromesRareVariable (often insidious)Acanthosis nigricans, disproportionate metabolic derangement, lipodystrophy.

A tiered framework helps organize causes while preserving clinical probability:

Common Causes

  • Polycystic ovary syndrome remains the dominant diagnosis
  • Non-classic congenital adrenal hyperplasia can mimic PCOS

Less Common but Clinically Significant

  • Ovarian hyperthecosis, especially postmenopause
  • Androgen-secreting ovarian or adrenal tumors
  • Cushing syndrome and acromegaly
  • Severe insulin resistance syndromes

The guidelines consistently return to probability balanced with vigilance. Most patients will fall into common categories, yet the clinician must remain attentive to the small group where the presentation deviates from the expected path.

That balance defines good endocrine practice. It avoids unnecessary alarm, while still respecting the consequences of a missed diagnosis.

Clinical Features That Guide Suspicion

Symptoms alone rarely provide the full answer, yet their pattern carries strong diagnostic value.

Common features include:

  • Hirsutism and acne
  • Scalp hair thinning
  • Menstrual irregularity

More concerning findings include:

  • Deepening voice
  • Clitoromegaly
  • Rapid muscle changes
  • Sudden onset symptoms

These “red flag” features shift the clinical posture from routine evaluation to urgent investigation. In practice, this transition often happens not because of a single lab value, but because the overall story no longer fits a benign trajectory.

The contrast between gradual evolution and abrupt change often carries more diagnostic value than the symptom itself.

Biochemical Evaluation: Precision Matters

BiomarkerPrimary OriginClinical Purpose & Red Flags
Total TestosteroneOvaries (primarily)The baseline metric. Levels > 5 nmol/L strongly suggest a tumor or severe pathology triggering urgent imaging.
DHEASAdrenal Glands (exclusively)Differentiates the source. An isolated, severe elevation points directly to an adrenal pathology.
Androstenedione (A4)Ovaries & AdrenalsProvides a combined picture of androgen precursor activity.
17-Hydroxyprogesterone (17-OHP)Adrenal GlandsEssential screening tool to rule out non-classic Congenital Adrenal Hyperplasia (CAH).
Sex Hormone Binding Globulin (SHBG)LiverUsed to calculate free testosterone. Lowered by high insulin, which amplifies active, free androgen levels.

The guidelines strongly emphasize careful laboratory strategy.

Core testing includes:

  • Total testosterone, ideally measured with LC-MS/MS
  • Free testosterone or calculated indices
  • DHEAS to assess adrenal contribution
  • Androstenedione for combined ovarian-adrenal insight
  • 17-hydroxyprogesterone to screen for CAH

Testing conditions matter. Samples should be collected in the morning, fasting, and ideally in the early follicular phase. Hormonal contraception should be discontinued beforehand when feasible.

Beyond technique, interpretation carries equal, if not greater, importance. Laboratory values must be read within clinical context. A number that appears modest in isolation may carry significance when paired with rapid symptom progression, while a higher value in a stable clinical picture may behave differently.

Imaging and Escalation Strategy

Imaging decisions follow clinical probability rather than routine use.

  • Suspected PCOS does not always require imaging if criteria are met
  • Ovarian ultrasound serves as first-line imaging when indicated
  • MRI improves detection of small ovarian tumors
  • CT or MRI evaluates adrenal pathology when biochemical patterns suggest adrenal origin

Severe testosterone elevation (specifically > 5 nmol/L) or rapid symptom progression should trigger urgent imaging.

This stepwise escalation reflects a broader principle. Testing should follow reasoning, not replace it. When imaging aligns with clinical suspicion, it confirms direction. When it does not, it prompts reconsideration rather than reflex escalation.

Role of Dynamic Testing

When routine evaluation remains inconclusive, dynamic endocrine testing can help localize the source of androgen excess.

  • GnRH suppression testing supports ovarian origin
  • Dexamethasone suppression testing evaluates adrenal contribution

These tools act as refinements rather than first-line tests. They help resolve ambiguity when standard pathways do not provide clarity, particularly in complex or overlapping presentations.

Patient Case Variations

These cases reflect how androgen excess can present across different clinical patterns. Each example highlights how symptoms, labs, and context come together in a meaningful way.

  • Case 1 — Classic PCOS Pattern: A 26-year-old woman presents with irregular cycles and gradual facial hair growth since adolescence. Her testosterone is mildly elevated, and ultrasound shows polycystic ovarian morphology. Insulin resistance contributes to her presentation. A structured plan focusing on metabolic health and cycle regulation improves both symptoms and labs.
  • Case 2 — Lean PCOS With Subtle Metabolic Signals: A 30-year-old woman with normal weight reports acne and irregular cycles. Her labs show elevated free testosterone with low-normal SHBG. Despite a lean frame, mild insulin resistance is present. Nutritional adjustments and targeted therapy improve her hormonal balance.
  • Case 3 — Non-classic CAH Mimicking PCOS: A 22-year-old woman presents with hirsutism and irregular menses. Initial evaluation suggests PCOS, yet 17-hydroxyprogesterone is elevated. Further testing confirms non-classic congenital adrenal hyperplasia. A tailored treatment approach addresses adrenal androgen production.
  • Case 4 — Rapid Onset Suggesting Ovarian Tumor: A 41-year-old woman develops worsening hirsutism and voice deepening over 4 months. Testosterone is markedly elevated above 5 nmol/L. Imaging reveals a small androgen-secreting ovarian tumor. Surgical removal resolves symptoms and normalizes hormone levels.
  • Case 5 — Postmenopausal Hyperthecosis: A 63-year-old woman reports new facial hair and scalp thinning. Testosterone is elevated, while DHEAS remains normal. Imaging shows enlarged ovaries without a discrete mass. The pattern suggests ovarian hyperthecosis, often linked with insulin resistance. Management focuses on both hormonal and metabolic factors.
  • Case 6 — Severe Insulin Resistance Driving Androgens: A 35-year-old woman presents with significant hirsutism, irregular cycles, and acanthosis nigricans. Her insulin levels are markedly elevated, and testosterone is high. The pattern reflects severe insulin resistance amplifying ovarian androgen production. Targeted metabolic therapy leads to meaningful improvement.
  • Case 7 — Adrenal Source of Androgen Excess: A 48-year-old woman develops new-onset acne and hair growth. Labs show elevated DHEAS with moderately increased testosterone. Imaging identifies an adrenal mass. Further evaluation distinguishes a functional adrenal source, guiding appropriate intervention.
  • Case 8 — Cushing-Related Androgen Excess: A 39-year-old woman presents with weight gain, fatigue, and irregular cycles. She also notes acne and mild hirsutism. Examination reveals central adiposity and subtle striae. Hormonal evaluation confirms cortisol excess contributing to androgen elevation. Treating the underlying condition improves her hormonal profile.
  • Case 9 — Acromegaly With PCOS-Like Features: A 44-year-old woman reports irregular cycles, increased shoe size, and fatigue. She also has mild androgen excess on labs. Elevated IGF-1 confirms acromegaly. Growth hormone excess contributes to insulin resistance and androgen changes. Treatment of acromegaly improves her metabolic and hormonal state.
  • Case 10 — Functional and Stress-Related Overlap: A 33-year-old woman reports acne, irregular cycles, and hair thinning during a period of chronic stress and poor sleep. Labs show borderline androgen elevation with low SHBG. No structural pathology is found. Improving sleep, stress, and metabolic patterns stabilizes her symptoms without aggressive intervention.

These variations highlight a central theme. The same symptom can reflect very different physiology. A thoughtful, pattern-based approach allows for more precise diagnosis and more meaningful care.

Metabolic and Long-Term Health Implications

The guidelines extend beyond diagnosis and highlight long-term health risks.

Androgen excess correlates strongly with:

This section carries important clinical gravitas. Androgen excess often represents an early visible marker of deeper metabolic stress. In many cases, it precedes overt disease by years.

Recognizing that trajectory allows for earlier, more meaningful intervention. It shifts the focus from symptom suppression to long-term physiologic stability.

Patient-Centered Considerations

The guidance also recognizes the psychological and social burden of androgen excess. Symptoms such as hirsutism or hair loss can significantly affect self-image, confidence, and quality of life. Many patients feel their concerns are minimized or misunderstood.

Therefore, effective care requires:

  • Thoughtful communication
  • Individualized management plans
  • Attention to mental and emotional impact

This dimension reinforces that endocrine care extends beyond laboratory interpretation. It involves understanding how physiology translates into lived experience.

Key Takeaway

These guidelines present a balanced and structured framework for evaluating androgen excess. They integrate clinical pattern recognition, precise biochemical testing, and targeted imaging to guide decision-making.

At their core, they encourage a more measured and integrated way of thinking. Rather than reacting to isolated findings, they promote interpretation through context, trajectory, and interconnected physiology.

Dr. Tashko

  1. Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women. Clinical Endocrinology. 2025. Elhassan YS, Hawley JM, Cussen L, et al.
  2. Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women. The Journal of Clinical Endocrinology and Metabolism. 2018. Elhassan YS, Idkowiak J, Smith K, et al.
  3. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism. 2018. Martin KA, Anderson RR, Chang RJ, et al.
  4. ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstetrics and Gynecology. 2018. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology.
  5. Polycystic Ovary Syndrome. The New England Journal of Medicine. 2016. McCartney CR, Marshall JC.
  6. Polycystic Ovary Syndrome: Common Questions and Answers. American Family Physician. 2023. Williams T, Moore JB, Regehr J.
  7. Polycystic Ovary Syndrome. The Lancet. Diabetes & Endocrinology. 2022. Joham AE, Norman RJ, Stener-Victorin E, et al.
  8. Screening and Management of the Hyperandrogenic Adolescent. American College of Obstetricians and Gynecologists (2019). 2019. Jennie Yoost, Ashlyn Savage

About Dr. Gerti Tashko, MD

Dr. Gerti Tashko, MD, is an endocrinologist in Montgomery County, Maryland. He is uniquely quadruple board-certified in endocrinology, lipidology, hypertension, and obesity medicine. His practice delivers root-cause-focused metabolic and endocrine care, available virtually and in person. He uses advanced diagnostics, personalized nutrition, and preventive medicine to improve long-term health.